Innovative biotech in pre-clinical contract research (CRO) services and proprietary early target and peptide drug discovery." title="" class="btn" data-container="body" data-html="true" data-id="285178" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#b3d4fc" tabindex="0" data-original-title="Gubra"> 181 17,496
Activities
Technologies
Entity types
Location
Hørsholm Kongevej 11B, 2970 Hørsholm, Denmark
Hørsholm
Denmark
Employees
Scale: 201-500
Estimated: 265
Engaged corporates
3Added in Motherbase
1 year, 11 months agoScience of certainty
Founded in 2008, we are a biotech company with two primary areas of business: Preclinical contract research organization (CRO) services and proprietary early target and drug discovery programs.
Our focus is the metabolic space (e.g. obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in peptide chemistry, in vivo pharmacology, ex vivo assays, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing) and bioinformatics.
Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise.
We work with some of the most interesting and loyal partners and customers from across the world in the pharmaceutical and biotech industry as well as academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.
in vivo pharmacology, histology, stereology, diabetes, obesity, NASH, Gastrointestinal diseases, peptide chemistry, molecular pharmacology, next generation sequencing, bioinformatics, ex vivo assays, and Imaging
Gubra is specialized in high-end preclinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() EU Green Capital European Union, Environmental Services | EU Green Capital European Union, Environmental Services | Other 24 Nov 2024 | | |
![]() Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 24 Nov 2024 | | |
![]() Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Other 2 Jul 2024 | |